Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.61 |
| ▸ | BCHE | P06276 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.53 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.53 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843080 | 1.00 | MAPT (0.73) | MAPTCYP1B1CYP1A1BCHECYP2C19 | |
| SCHEMBL14801668 | 0.89 | MAPT (0.60) | MAPTCYP1B1CYP1A1BCHECYP2C19 | |
| SCHEMBL14801670 | 0.89 | MAPT (0.60) | MAPTCYP1B1CYP1A1BCHECYP2C19 | |
| SCHEMBL27753446 | 0.87 | MAPT (0.78) | MAPTCYP1B1CYP1A1BCHECYP2C19 | |
| SCHEMBL1501351 | 0.84 | MAPT (1.00) | MAPTCYP1B1CYP1A1BCHECYP2C19 | |
| SCHEMBL1501349 | 0.84 | MAPT (1.00) | MAPTCYP1B1CYP1A1BCHECYP2C19 | |
| SCHEMBL25202121 | 0.84 | MAPT (0.73) | MAPTCYP1B1BCHECYP2C19MAOB | |
| SCHEMBL17047852 | 0.84 | MAPT (0.73) | MAPTCYP1B1BCHECYP2C19MAOB | |
| SCHEMBL31233508 | 0.84 | MAPT (0.73) | MAPTCYP1B1BCHECYP2C19MAOB | |
| SCHEMBL30383301 | 0.84 | MAPT (0.73) | MAPTCYP1B1BCHECYP2C19MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140072584-A1 | NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES | LI, YINGJI (CN) | 2014-03-13 | — | — | US | claimed |
| US-4623724-A | Method for the production of nuclear substituted cinnamoylanthranilic acid salts | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1986-11-18 | — | — | US | claimed |
| US-4587356-A | Process for the production of nuclear substituted cinnamoylanthranilic acid derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1986-05-06 | — | — | US | claimed |
| EP-0074725-B1 | A METHOD FOR THE PRODUCTION OF NUCLEAR SUBSTITUTED CINNAMOYLANTHRANILIC ACID DERIVATIVES AND INTERMEDIATES THEREOF | Kissei Pharmaceutical Co. Ltd. (JP) | 1985-12-27 | — | — | EP | claimed |
| US-4486597-A | Method for the production of nuclear substituted cinnamoylanthranilic acid derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1984-12-04 | — | — | US | claimed |
| EP-0074725-A1 | A method for the production of nuclear substituted cinnamoylanthranilic acid derivatives and intermediates thereof | Kissei Pharmaceutical Co. Ltd. (JP) | 1983-03-23 | — | — | EP | claimed |
| JP-1246249-A | — | — | None | — | — | JP | disclosed |
| US-20230270703-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | OCCURX PTY LTD (AU) | 2023-08-31 | — | — | US | disclosed |
| CN-116033901-A | Compounds and methods for treating ocular disorders | 奥克尔克斯有限公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-4161527-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | OccuRx Pty Ltd (AU) | 2023-04-12 | — | — | EP | disclosed |
| EP-2799427-B1 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| CN-107643344-A | Utilize high performance liquid chromatography fluoroscopic examination（HPLC‑FLD）Method analysis measure oat alkaloid | 北京工商大学 | 2018-01-30 | — | — | CN | disclosed |
| US-9561201-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2017-02-07 | — | — | US | disclosed |
| EP-0074725-B1 | A METHOD FOR THE PRODUCTION OF NUCLEAR SUBSTITUTED CINNAMOYLANTHRANILIC ACID DERIVATIVES AND INTERMEDIATES THEREOF | Kissei Pharmaceutical Co. Ltd. (JP) | 1985-12-27 | — | — | EP | disclosed |
| US-4486597-A | Method for the production of nuclear substituted cinnamoylanthranilic acid derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1984-12-04 | — | — | US | disclosed |
| US-4486597-A | Method for the production of nuclear substituted cinnamoylanthranilic acid derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1984-12-04 | — | — | US | disclosed |
| US-4486597-A | Method for the production of nuclear substituted cinnamoylanthranilic acid derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1984-12-04 | — | — | US | disclosed |
| EP-0074725-A1 | A method for the production of nuclear substituted cinnamoylanthranilic acid derivatives and intermediates thereof | Kissei Pharmaceutical Co. Ltd. (JP) | 1983-03-23 | — | — | EP | disclosed |
| EP-0074725-A1 | A method for the production of nuclear substituted cinnamoylanthranilic acid derivatives and intermediates thereof | Kissei Pharmaceutical Co. Ltd. (JP) | 1983-03-23 | — | — | EP | disclosed |
| EP-0074725-A1 | A method for the production of nuclear substituted cinnamoylanthranilic acid derivatives and intermediates thereof | Kissei Pharmaceutical Co. Ltd. (JP) | 1983-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140072584-A1 | NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES | NFATC1, GABRA5, GABRA6 | MAPT 4128/4885CYP1B1 515/4885CYP1A1 743/4885 |
| US-20230270703-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | ALDH1A2, RBP4, RARB | MAPT 3298/4885CYP1B1 1885/4885CYP1A1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.